TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Akari Therapeutics ( (AKTX) ) has issued an announcement.
Akari Therapeutics has announced a Peak Bio Note and Loan Cancellation Agreement. This agreement may have implications for the company’s financial operations and its positioning within the industry.
The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Average Trading Volume: 27,530
Technical Sentiment Signal: Sell
Current Market Cap: $32.33M
For detailed information about AKTX stock, go to TipRanks’ Stock Analysis page.